Results 171 to 180 of about 2,442,464 (298)
Generic Drug Usage in Dentistry across Japan: Analysis Using a Japanese National Database. [PDF]
Ono S +5 more
europepmc +1 more source
Researchers developed an engineered probiotic encapsulated in an inulin hydrogel, enabling ultrasound‐triggered intestinal delivery of IL‐22. In MASH model mice, this system remodeled gut microbiota, strengthened the intestinal barrier and reduced portal LPS and hepatic IL‐6.
Chunya Ji +11 more
wiley +1 more source
This study identifies GAP2, a bioactive polysaccharide fraction derived from Ganoderma applanatum, as a postbiotic inducer that repairs intestinal barrier damage in a gut microbiota‐dependent manner. GAP2 enriches Phocaeicola vulgatus, which degrades GAP2 and promotes tridecylic acid production, triggering Rho/CDC42 signaling and tight‐junction ...
Chuan Zhang +10 more
wiley +1 more source
Estimating the Value of Adding 30 Days to the 180-Day Market Exclusivity of the First-to-File Generic Drug Manufacturer. [PDF]
Sertkaya A +5 more
europepmc +1 more source
A Physician's Perspective on Generic Drug Quality. [PDF]
Lever HM.
europepmc +1 more source
Fluorinated β‐glucan/pectin nanogels enable colon‐targeted oral delivery of astilbin through gastrointestinal protection, β‐glucanase‐responsive release, mucus penetration, and prolonged retention. The released astilbin attenuates senescence‐associated features of CD4+ T cells and promotes Treg responses, while the nanogel matrix modulates the gut ...
Lei Zhao +11 more
wiley +1 more source
Pharmacokinetics and Generic Drug Switching: A Regulator's View. [PDF]
Glerum PJ +4 more
europepmc +1 more source
Background: One way to reduce cost of health services is increased use of generic drug. For that reason. the choice of prescribing generic drug or non-generic one among medical practitioners was studied.
Perpustakaan UGM, i-lib
core +1 more source
Parkinson's disease currently has no disease‐modifying therapies. In Caenorhabditis elegans, Escherichia coli E8 alleviates α‐synuclein‐provoked PD‐related defects through its bioactive metabolite 1‐ALPP, which combats PD by triggering AMPK/mTOR/HLH‐30‐dependent autophagy and suppressing α‐synuclein LLPS‐mediated fibrillization.
Mingqin Qu +12 more
wiley +1 more source

